Form 4: ImageneBio Director Reports Share Acquisition Following Merger and Reverse Stock Split

ImageneBio, Inc. Director Otello Stampacchia reported the acquisition of shares by an affiliated entity and the cancellation of stock options, following the company's merger with Inmagene Biopharmaceuticals and a 1:12 reverse stock split.

Summary

• Reporting Person Otello Stampacchia, a Director and 10% Owner of ImageneBio, Inc., filed a Form 4.
• The filing details transactions occurring on July 25, 2025, related to the merger of Ikena Oncology, Inc. (now ImageneBio, Inc.) with Inmagene Biopharmaceuticals.
• A 1:12 reverse stock split was effective on July 25, 2025, prior to the merger's first effective time.
• Unexpired, unexercised, and unvested Ikena options were fully accelerated, and fully vested options were cancelled and exchanged for Ikena common stock.
• Specifically, 17,520 stock options with an exercise price of $1.75 were exchanged for 379 shares of Issuer common stock.
• Omega Fund VI, L.P., an entity where the Reporting Person is a director of its general partner's manager, purchased 267,556 shares of ImageneBio common stock at approximately $29.90 per share.
• This purchase was part of a larger Private Investment in Public Equity (PIPE) transaction where investors subscribed for an aggregate of 2,508,337 shares at $29.90 per share, raising approximately $75.0 million.
• Following these transactions, the Reporting Person holds 0 shares directly and 454,982 shares indirectly through Omega Fund VI, L.P.

Sentiment

Score: 7

Explanation: The filing reports the completion of a significant strategic merger and a substantial capital raise, which are generally positive for a company's long-term prospects and financial stability. While a reverse stock split can be viewed negatively, it was part of a larger strategic transaction aimed at restructuring and recapitalizing the company. The insider's affiliated entity participating in the PIPE also indicates confidence.

Positives

• Successful completion of the merger between Ikena Oncology, Inc. and Inmagene Biopharmaceuticals, forming ImageneBio, Inc., which can lead to synergistic benefits and an expanded pipeline.
• Completion of a Private Investment in Public Equity (PIPE) financing raising approximately $75.0 million, providing significant capital for the combined entity.
• A director's affiliated entity participated in the PIPE, indicating continued investment and confidence from key stakeholders.

Negatives

• A 1:12 reverse stock split was implemented, which often indicates a company's stock price has fallen significantly and can be perceived negatively by investors, potentially impacting liquidity and investor sentiment.
• The cancellation of stock options in exchange for shares, while a part of the merger terms, represents a change in the nature of the incentive for option holders.

Risks

• Reverse stock splits can sometimes lead to decreased liquidity and may not always improve stock price performance in the long term.
• Integration risks associated with the merger of two biopharmaceutical companies (Ikena Oncology and Inmagene Biopharmaceuticals).
• Potential dilution for existing shareholders from the PIPE financing, although it provides capital.

Future Outlook

The filing details the completion of a strategic merger between Ikena Oncology, Inc. and Inmagene Biopharmaceuticals, which has resulted in the formation of ImageneBio, Inc. This strategic move, coupled with a significant capital raise, positions the newly formed entity for future operations and development in the biopharmaceutical sector.

Industry Context

The merger of Ikena Oncology and Inmagene Biopharmaceuticals reflects a trend in the biotechnology and pharmaceutical sectors where companies combine to consolidate pipelines, expand therapeutic areas, and achieve greater scale. The accompanying PIPE financing is a common method for biotech companies to raise substantial capital, especially after significant corporate actions like mergers, to fund research, development, and operational expenses. The reverse stock split is often a measure taken by companies to meet listing requirements or improve stock attractiveness, a common occurrence in the volatile biotech market.

Comparison to Industry Standards

• Mergers and acquisitions are a common strategy in the biopharmaceutical industry for pipeline expansion and market consolidation, similar to recent deals involving companies like Bristol Myers Squibb acquiring Karuna Therapeutics or AbbVie acquiring Cerevel Therapeutics.
• Private Investment in Public Equity (PIPE) transactions are a standard financing mechanism for public biotech companies, particularly after significant corporate events, to raise capital from institutional investors. The $75.0 million raise is a substantial amount, comparable to PIPE financings seen in other emerging biotech firms.
• Reverse stock splits are frequently observed in the biotech sector, often employed by companies whose stock prices have fallen below exchange minimums or to enhance perceived value, similar to actions taken by companies like Sorrento Therapeutics or Cassava Sciences in the past.

Corporate Governance

Related Party Transactions

• Omega Fund VI, L.P. purchased 267,556 shares of Issuer common stock as part of the PIPE financing. The Reporting Person, Otello Stampacchia, is a director of Omega Fund VI GP Manager, Ltd., which is the sole general partner of Omega Fund VI GP, L.P., the sole general partner of Omega Fund VI, L.P. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The 1:12 reverse stock split significantly reduces the number of outstanding shares and increases the per-share price, which can impact liquidity and investor perception. The merger changes the fundamental business and asset base of the company. The PIPE financing, while providing capital, also results in dilution for existing shareholders.
• Employees: The merger likely impacts employees of both Ikena Oncology and Inmagene Biopharmaceuticals through integration processes and potential restructuring. The acceleration of Ikena options affects employee compensation.
• Creditors: The capital raise strengthens the company's financial position, potentially improving its ability to meet obligations.

Next Steps

• Integration of Legacy Inmagene into ImageneBio, Inc. operations.
• Deployment of the $75.0 million capital raised from the PIPE financing for future business activities.

Key Dates

Recommendation

The filing details the completion of a significant strategic merger and a substantial capital raise, which are positive for the company's long-term stability and growth prospects. However, the simultaneous 1:12 reverse stock split, while a necessary part of the transaction, can be a red flag for some investors as it often follows a period of significant stock price decline. While the capital infusion is beneficial, the immediate impact on the stock price due to the reverse split and the integration risks of the merger warrant a cautious 'hold' stance until the combined entity's operational performance and market reception can be further assessed. The insider's affiliated entity participating in the PIPE is a positive signal, but the overall picture requires observation.

Keywords

ImageneBio, Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Reverse Stock Split, PIPE, Private Placement, Form 4, Insider Trading, Biotechnology, Pharmaceuticals, Stock Option, Capital Raise, Corporate Governance